Chad Artman1, Kyle D Brumfield2,3, Sahil Khanna4, Julius Goepp1. 1. Scaled Microbiomics, LLC, Hagerstown, MD, United States of America. 2. Maryland Pathogen Research Institute, University of Maryland, College Park, MD, United States of America. 3. University of Maryland Institute for Advanced Computer Studies, University of Maryland, College Park, MD, United States of America. 4. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States of America.
Abstract
BACKGROUND: The global pandemic of Coronavirus infectious disease 2019 (COVID-19), caused by SARS-CoV-2, has plunged the world into both social and economic disarray, with vaccines still emerging and a continued paucity of personal protective equipment; the pandemic has also highlighted the potential for rapid emergence of aggressive respiratory pathogens and the need for preparedness. Avian immunoglobulins (IgY) have been previously shown in animal models to protect against new infection and mitigate established infection when applied intranasally. We carried out a proof-of-concept study to address the feasibility of using such antibodies as mucosally-applied prophylaxis against SARS-CoV-2. METHODS: Hens were immunized with recombinant S1 spike glycoprotein of the virus, and the resulting IgY was evaluated for binding specificity, inhibition of glycoprotein binding to angiotensin converting enzyme-2 (ACE2) protein (the requisite binding site for the virus), and inhibition of viral replication in Vero cell culture. RESULTS: Titers of anti-S1 glycoprotein IgY were evident in yolks at 14 days post-immunization, peaking at 21 days, and at peak concentrations of 16.8 mg/ml. IgY showed strong and significant inhibition of S1/ACE2 binding interactions, and significantly inhibited viral replication at a concentration of 16.8 mg/ml. Four weeks' collection from eggs of two hens produced a total of 1.55 grams of IgY. CONCLUSIONS: In this proof-of-concept study we showed that avian immunoglobulins (IgY) raised against a key virulence factor of the SARS-CoV-2 virus successfully inhibited the critical initial adhesion of viral spike glycoproteins to human ACE2 protein receptors and inhibited viral replication in vitro, in a short period using only two laying hens. We conclude that production of large amounts of IgY inhibiting viral binding and replication of SARS-CoV-2 is feasible, and that incorporation of this or similar material into an intranasal spray and/or other mucosal protecting products may be effective at reducing infection and spread of COVID-19.
BACKGROUND: The global pandemic of Coronavirus infectious disease 2019 (COVID-19), caused by SARS-CoV-2, has plunged the world into both social and economic disarray, with vaccines still emerging and a continued paucity of personal protective equipment; the pandemic has also highlighted the potential for rapid emergence of aggressive respiratory pathogens and the need for preparedness. Avian immunoglobulins (IgY) have been previously shown in animal models to protect against new infection and mitigate established infection when applied intranasally. We carried out a proof-of-concept study to address the feasibility of using such antibodies as mucosally-applied prophylaxis against SARS-CoV-2. METHODS:Hens were immunized with recombinant S1 spike glycoprotein of the virus, and the resulting IgY was evaluated for binding specificity, inhibition of glycoprotein binding to angiotensin converting enzyme-2 (ACE2) protein (the requisite binding site for the virus), and inhibition of viral replication in Vero cell culture. RESULTS: Titers of anti-S1 glycoprotein IgY were evident in yolks at 14 days post-immunization, peaking at 21 days, and at peak concentrations of 16.8 mg/ml. IgY showed strong and significant inhibition of S1/ACE2 binding interactions, and significantly inhibited viral replication at a concentration of 16.8 mg/ml. Four weeks' collection from eggs of two hens produced a total of 1.55 grams of IgY. CONCLUSIONS: In this proof-of-concept study we showed that avian immunoglobulins (IgY) raised against a key virulence factor of the SARS-CoV-2 virus successfully inhibited the critical initial adhesion of viral spike glycoproteins to humanACE2 protein receptors and inhibited viral replication in vitro, in a short period using only two laying hens. We conclude that production of large amounts of IgY inhibiting viral binding and replication of SARS-CoV-2 is feasible, and that incorporation of this or similar material into an intranasal spray and/or other mucosal protecting products may be effective at reducing infection and spread of COVID-19.
Authors: Lyn R Frumkin; Michaela Lucas; Curtis L Scribner; Nastassja Ortega-Heinly; Jayden Rogers; Gang Yin; Trevor J Hallam; Alice Yam; Kristin Bedard; Rebecca Begley; Courtney A Cohen; Catherine V Badger; Shawn A Abbasi; John M Dye; Brian McMillan; Michael Wallach; Traci L Bricker; Astha Joshi; Adrianus C M Boon; Suman Pokhrel; Benjamin R Kraemer; Lucia Lee; Stephen Kargotich; Mahima Agochiya; Tom St John; Daria Mochly-Rosen Journal: Front Immunol Date: 2022-06-01 Impact factor: 8.786
Authors: Andres Agurto-Arteaga; Astrid Poma-Acevedo; Dora Rios-Matos; Ricardo Choque-Guevara; Ricardo Montesinos-Millán; Ángela Montalván; Gisela Isasi-Rivas; Yudith Cauna-Orocollo; María de Grecia Cauti-Mendoza; Norma Pérez-Martínez; Kristel Gutierrez-Manchay; Ingrid Ramirez-Ortiz; Dennis Núñez-Fernández; Mario I Salguedo-Bohorquez; Stefany Quiñones-Garcia; Manolo Fernández Díaz; Luis A Guevara Sarmiento; Mirko Zimic Journal: Front Immunol Date: 2022-05-10 Impact factor: 8.786
Authors: Carrie J Chen; Anna F Hudson; Allison S Jia; Caitlin R Kunchur; Andrew J Song; Edward Tran; Chris J Fisher; Davide Zanchi; Lucia Lee; Stephen Kargotich; Mary Romeo; Ana Koperniku; Ravinder D Pamnani; Daria Mochly-Rosen Journal: J Glob Health Date: 2022-02-26 Impact factor: 4.413
Authors: Sherif A El-Kafrawy; Abby Odle; Aymn T Abbas; Ahmed M Hassan; Umama A Abdel-Dayem; Arooj K Qureshi; Lok-Yin Roy Wong; Jian Zheng; David K Meyerholz; Stanley Perlman; Alimuddin Zumla; Esam I Azhar Journal: PLoS Pathog Date: 2022-09-19 Impact factor: 7.464
Authors: Hendris Wongso; Isa Mahendra; Wyanda Arnafia; Idar Idar; Muhammad Yusuf; Arifudin Achmad; Holis A Holik; Ahmad Kurniawan; Iim Halimah; Maula E Sriyani; Teguh H A Wibawa; Muhamad B Febrian; Yanuar Setiadi; Eva M Widyasari; Isti Daruwati; Crhisterra E Kusumaningrum; Toto Subroto Journal: Vaccines (Basel) Date: 2022-01-17